Institute of Human Virology HIV Vaccine Research Trial

This is a Phase 1 randomized, placebo-controlled, modified double-blinded clinical trial designed to evaluate the safety and immunogenicity of a HIV vaccine called FLSC (full-length single chain) in healthy volunteers without HIV infection. This novel vaccine was developed by investigators at the Institute of Human Virology as a potential future strategy to help prevent HIV infection.

Volunteers must be:

  • healthy,
  • 18-45 years of age,
  • HIV negative,
  • and have never previously participated in an HIV or DNA vaccine trial.

Compensation will be given for travel and expenses.

Nora Grannell Bulletin Board, Clinical Care, Research, UMB NewsAugust 22, 20160 commentsHIV Vaccine Research Trial, Institute of Human Virology, University of Maryland Baltimore School of Medicine.

Leave a Comment

Your email address will not be published. Required fields are marked *